DK62692D0 - - Google Patents

Info

Publication number
DK62692D0
DK62692D0 DK92626A DK62692A DK62692D0 DK 62692 D0 DK62692 D0 DK 62692D0 DK 92626 A DK92626 A DK 92626A DK 62692 A DK62692 A DK 62692A DK 62692 D0 DK62692 D0 DK 62692D0
Authority
DK
Denmark
Application number
DK92626A
Other languages
Danish (da)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to DK92626A priority Critical patent/DK62692D0/da
Publication of DK62692D0 publication Critical patent/DK62692D0/da
Priority to IL105673A priority patent/IL105673A/en
Priority to NZ252110A priority patent/NZ252110A/en
Priority to AU40612/93A priority patent/AU671995B2/en
Priority to CA002113547A priority patent/CA2113547A1/fr
Priority to EP93909822A priority patent/EP0603348A1/fr
Priority to PCT/DK1993/000158 priority patent/WO1993023418A1/fr
Priority to JP5519787A priority patent/JPH06508855A/ja
Priority to NO940123A priority patent/NO940123L/no
Priority to FI940167A priority patent/FI940167A/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK92626A 1992-05-14 1992-05-14 DK62692D0 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DK92626A DK62692D0 (fr) 1992-05-14 1992-05-14
IL105673A IL105673A (en) 1992-05-14 1993-05-11 Use of n-substituted adenosine derivatives for the preparation of medicaments for treating myocardial or cerebral ischemia, certain novel n-substituted adenosine derivatives and pharmaceutical compositions containing them
NZ252110A NZ252110A (en) 1992-05-14 1993-05-12 Adenosine derivatives and pharmaceutical compositions
AU40612/93A AU671995B2 (en) 1992-05-14 1993-05-12 Purine derivatives
CA002113547A CA2113547A1 (fr) 1992-05-14 1993-05-12 Derives puriniques
EP93909822A EP0603348A1 (fr) 1992-05-14 1993-05-12 Derives de la purine
PCT/DK1993/000158 WO1993023418A1 (fr) 1992-05-14 1993-05-12 Derives de la purine
JP5519787A JPH06508855A (ja) 1992-05-14 1993-05-12 プリン誘導体
NO940123A NO940123L (no) 1992-05-14 1994-01-13 Purinderivater
FI940167A FI940167A (fi) 1992-05-14 1994-01-13 Puriinijohdannaisia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK92626A DK62692D0 (fr) 1992-05-14 1992-05-14

Publications (1)

Publication Number Publication Date
DK62692D0 true DK62692D0 (fr) 1992-05-14

Family

ID=8095717

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92626A DK62692D0 (fr) 1992-05-14 1992-05-14

Country Status (9)

Country Link
EP (1) EP0603348A1 (fr)
JP (1) JPH06508855A (fr)
AU (1) AU671995B2 (fr)
CA (1) CA2113547A1 (fr)
DK (1) DK62692D0 (fr)
FI (1) FI940167A (fr)
IL (1) IL105673A (fr)
NZ (1) NZ252110A (fr)
WO (1) WO1993023418A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK155292D0 (da) * 1992-12-23 1992-12-23 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
BR9507683A (pt) * 1994-05-10 1997-09-23 Sandoz Ag Derivados de adenosina
EP0704215A3 (fr) * 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibiteur de l'aumentation de la perméabilité vasculaire
GB9421133D0 (en) * 1994-10-20 1994-12-07 Glaxo Group Ltd Medicaments
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
AU2001260076A1 (en) * 2000-05-15 2001-11-26 Novo-Nordisk A/S Compounds for treating disorders where a decreased level of plasma ffa is desired
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
EP2021350B1 (fr) 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Agonistes du récepteur a2a phosphorylé
CZ2009298A3 (cs) * 2009-05-14 2010-11-24 Univerzita Palackého v Olomouci Substituované 6-benzylaminopurin ribosidy, jejich použití a farmaceutický prípravek tyto slouceniny obsahující
CN102711771B (zh) 2010-01-11 2016-05-18 伊诺泰克制药公司 降低眼压的组合、试剂盒和方法
CN102933593A (zh) 2010-03-26 2013-02-13 伊诺泰克制药公司 使用n6-环戊基腺苷(cpa)、cpa衍生物或其前药降低人眼内压的方法
KR20130029049A (ko) * 2010-03-26 2013-03-21 이노텍 파마슈티컬스 코포레이션 아데노신 화합물 및 이의 용도
EA027109B1 (ru) 2012-01-26 2017-06-30 Инотек Фармасьютикалс Корпорейшн Безводные полиморфы [(2r,3s,4r,5r)-5-(6-(циклопентиламино)-9h-пурин-9-ил)-3,4-дигидрокситетрагидрофуран-2-ил]метилнитрата и способы их получения
MX2015013234A (es) 2013-03-15 2016-04-15 Inotek Pharmaceuticals Corp Formulaciones oftalmicas.
JP2015172077A (ja) * 2015-06-24 2015-10-01 中国医学科学院葯物研究所 N6−置換アデノシン誘導体とn6−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途
GB2582361A (en) * 2019-03-21 2020-09-23 Univ Warwick Adenosine receptor agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL128629C (fr) * 1966-05-07
DE1670077C3 (de) * 1966-05-07 1975-04-24 Boehringer Mannheim Gmbh, 6800 Mannheim Adenosin-Derivate und Verfahren zu ihrer Herstellung
NL6717061A (fr) * 1966-12-21 1968-06-24
DE2052596A1 (de) * 1970-10-27 1972-05-04 Boehringer Mannheim Gmbh, 6800 Mannheim Neuartige Verwendung von N(6)-substituierten Adenosin-Derivaten
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
ATE50777T1 (de) * 1984-04-18 1990-03-15 Whitby Research Inc Cardio-vasodilatatore n-6-substituierte adenosine.
US4791103A (en) * 1985-02-08 1988-12-13 Warner-Lambert Company 2,N6 -disubstituted adenosines, derivatives and methods of use
JPH0696534B2 (ja) * 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
DK62592D0 (fr) * 1992-05-14 1992-05-14 Novo Nordisk As

Also Published As

Publication number Publication date
EP0603348A1 (fr) 1994-06-29
IL105673A (en) 1998-01-04
AU671995B2 (en) 1996-09-19
WO1993023418A1 (fr) 1993-11-25
FI940167A (fi) 1994-03-03
JPH06508855A (ja) 1994-10-06
FI940167A0 (fi) 1994-01-13
CA2113547A1 (fr) 1993-11-25
AU4061293A (en) 1993-12-13
NZ252110A (en) 1996-07-26
IL105673A0 (en) 1993-09-22

Similar Documents

Publication Publication Date Title
DK0613608T3 (fr)
TW250496B (fr)
DK0630289T3 (fr)
TW268973B (fr)
BR9304651A (fr)
DK62692D0 (fr)
DK0596750T3 (fr)
BR9207065A (fr)
DK0553681T3 (fr)
DK0588007T3 (fr)
DK0581129T3 (fr)
FR2688751B1 (fr)
DK0564197T3 (fr)
DK0574276T3 (fr)
TW256848B (fr)
DK0596569T3 (fr)
DK0581726T3 (fr)
DK0597323T3 (fr)
DK0576097T3 (fr)
DK0590732T3 (fr)
DE9207553U1 (fr)
AU632452B2 (fr)
IN176518B (fr)
IN185156B (fr)
AU2098792A (fr)